Evotec AG reported consolidated earnings results for the first quarter ended March 2013. Revenues for the first three months of 2013 decreased by 15% to EUR 17.1 million against EUR 20.1 million a year ago. Revenues for the first three months of the previous year included a milestone earned in company’s development partnership with Andromeda/Teva with DiaPep277. Excluding milestones, company’s revenues for the first quarter 2013 would have increased by 5% over the same period of the previous year. This growth was driven by an increase in revenues within the company's drug discovery alliances and from new integrated collaborations such as the CureBeta partnership with Janssen Pharmaceuticals and the multi-target alliance with Bayer entered into in the second half of 2012. Operating loss for the first quarter of 2013 was EUR 2.7 million due to absence of milestone revenues against EUR 0.9 million a year ago. Net loss was EUR 2.85 million against EUR 1.96 million a year ago. Net loss per share was EUR 0.02 against EUR 0.02 per share a year ago. The company confirmed earnings guidance for the year 2013. They expects revenues to grow to a level between EUR 90 million and EUR 100 million. This assumption is based on the current order book, expected new contracts and contract extensions and on the achievement of certain milestone payments. The company expects research and development expenses in 2013 to increase above the levels of 2012. This is primarily due to additional investments in the strategic Cure X franchise primarily in the fields of metabolic diseases and regenerative medicine. In total, R&D expenses are expected to be around EUR 10 million in 2013. Operating result before impairment and changes in contingent consideration, if any, is expected to improve over 2012.

Evotec AG, Q1 2013 Earnings Call, May 14, 2013

The Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Institute and Evotec AG announced research collaboration aimed at discovering and commercializing novel cancer treatments based on epigenetic drug mechanisms. The goal of the collaboration is to validate emerging epigenetic targets for oncology indications and to demonstrate the drugability of the selected target families. Evotec, Dana-Farber and Dana-Farber's Belfer Institute for Applied Cancer Science will invest in enabling technologies, experimental target validation and the generation of chemical matter by leveraging existing expertise and platforms. The collaboration will be fuelled by substantial scientific contributions from the three organizations aligned on the objective to develop therapies that address unmet medical needs for cancer patients. Epigenetics is a rapidly evolving high potential field of pharmaceutical research, calling for close relationships between academia and biotechnology innovators. By combining the complimentary capabilities of Dana-Farber, the Belfer Institute for Applied Cancer Science and Evotec this collaboration is uniquely positioned to succeed.